stockrow
Saturday 7 November 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024.
- EPS
- −35.3%
- Free cash flow
- −41.0%
Quarter to September 2026, against a year earlier
28.26
2.33
+8.99%
Follow ZBIO
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Piotroski F-Score |
2 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
1.73 | (0.82) | — | — |
Altman Z″-Score (non-manufacturers) |
(6.48) | 4.61 | (11.97) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(30.99) | (2.80) | (0.92) | — |
P/B ratio |
6.71 | 0.35 | 0.00 | — |
Price to Tangible BV |
6.71 | 0.35 | 0.00 | — |
EV/Sales |
0.00 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 1.44 | 0.00 | — |
EV/Operating CF |
(7.89) | 2.03 | 0.48 | — |
EV/FCF |
(7.89) | 2.03 | 0.48 | — |
Quick Ratio |
5.48 | 6.12 | 2.44 | 2.59 |
Current Ratio |
5.61 | 6.21 | 2.57 | 2.64 |
Net Debt/EBITDA |
0.69 | 2.14 | 0.99 | 0.88 |
Debt/Assets |
20.50% | 0.00% | 29.77% | 0.00% |
Debt/Equity |
0.32 | 0.00 | (0.09) | 0.00 |
Asset Turnover |
0.03 | 0.02 | 0.70 | — |
Operating CF/Net income |
0.46 | 0.76 | 0.82 | 0.55 |
Capex/Depreciation |
(0.32) | (0.96) | (0.15) | (2.54) |
Interest Coverage |
(52.28) | — | — | — |
| (136.22%) | (361.99%) | 17.76% | 0.00% | |
| (100.25%) | (71.66%) | (52.01%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(130.91%) | (52.54%) | (101.05%) | (279.15%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
1,680.63% | 2,782.78% | 120.07% | 0.00% |
Selling, General and Administrative Expense of Revenue |
533.22% | 594.98% | 34.23% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
263.47% | 216.42% | 6.99% | 0.00% |
Graham Net Nets |
0.13 | 2.76 | (6.98) | — |
Graham Number |
0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(21.51%) | (590.94%) | (264.33%) | — |
Free Cash Flow Yield |
(10.61%) | (110.83%) | (284.31%) | — |
Revenue per Share |
0.22 | 0.38 | 32.66 | 0.00 |
Operating CF per Share |
(3.85) | (9.07) | (19.94) | (44.00) |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.13) |
Free Cash Flow per Share |
(3.85) | (9.08) | (19.95) | (44.14) |
Cash per Share |
7.67 | 26.58 | 37.14 | 45.05 |
Shareholders Equity per Share |
5.41 | 23.67 | (147.43) | (128.88) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.41 | 23.67 | (147.43) | (128.88) |
Free Cash Flow |
(172.35) | (119.80) | (30.55) | (65.85) |
Working Capital |
288.52 | 298.63 | 36.55 | 42.48 |
Capital Expenditures |
(0.02) | (0.13) | (0.02) | (0.20) |
Net Current Asset Value |
209.68 | 298.41 | (234.10) | (198.42) |
EV/EBIT |
0.00 | 1.48 | 0.00 | — |
Capex to Sales |
0.00 | 0.03 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — |
| Other line items | ||||
Depreciation/Fixed assets |
1.65 | 0.74 | 0.59 | 0.31 |
Cash ROIC |
(25.96%) | (18.06%) | 20.56% | 52.65% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
12.12 | 11.27 | 5.61 | — |
Average Assets |
376.80 | 219.07 | 71.38 | — |
Average Common Equity |
277.30 | 43.37 | (209.00) | — |
Columns are period end dates · fundamentals updated 5 Nov 2026